{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:22:28Z","timestamp":1794331348992,"version":"4.9.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical outcomes, and biomarker characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, retrospective cohort study was conducted, patients diagnosed with CIDP were enrolled if they had received at least one course of ripertamab, rituximab, or efgartigimod. A total of 60 patients were included. At baseline and at each follow-up time point, the clinical results were evaluated by disease-specific grading scale, and the correlations between biomarker spectrum and disease activity was explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 patients were enrolled, with 27, 19, and 14 patients assigned to the rituximab, ripertamab, and efgartigimod groups, At the 3-month post-treatment assessment, the mean of the INCAT score decreased by 0.519 points in the rituximab group, 1.737 points in the ripertamab group, and 0.214 points in the efgartigimod group as compared to baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ripertamab demonstrated efficacy in managing short-term disease outcomes in patients with CIDP, with no significant difference observed when compared to rituximab or efgartigimod. These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1825584","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:21Z","timestamp":1779169161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yutong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanshuang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchao","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiliang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyou","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000494291","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01117-3","article-title":"Novel immunological and therapeutic insights in guillain-barr\u00e9 syndrome and CIDP","volume":"18","author":"Querol","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01221-y","article-title":"The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies","volume":"19","author":"Querol","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100903","article-title":"Plasma lipidomic patterns associated with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy (LIPID-CIDP)","volume":"66","author":"Auf dem Brinke","year":"2025","journal-title":"J Lipid Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3054","article-title":"Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera\u00ae) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: a randomized, single-blind, phase III clinical trial","volume":"40","author":"Shi","year":"2022","journal-title":"Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.06.08","article-title":"A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera\u00ae) in patients with CD20-positive B-cell non-Hodgkin lymphoma","volume":"34","author":"Han","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540694","article-title":"Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"20567","DOI":"10.1038\/s41598-025-06046-1","article-title":"The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2409353","article-title":"A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy","volume":"46","author":"Wang","year":"2024","journal-title":"Ren Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:21Z","timestamp":1779169161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1825584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825584","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825584.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1825584"}}